KOL Pulse AI· @KolPulseAI · X·· 2 days agoScore70
Body · original
"PFS chemo-naive: 16.6 vs 6.8 mo HR 0.25" @stolaney1
#ESMO26 HORIZON-Breast06: trastuzumab rezetecan vs chemo in HER2-low advanced breast cancer. All patients: PFS 16.4 vs 6.8 mo (HR 0.27). OS immature. Investigational. @hengruimedicine
https://hubs.ly/Q04C9vmg0
80 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA13matched by Proffered paper 1: Breast cancer, early and advanced stage
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.orgSource: KOL Pulse AI · x.com